Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Fixation of Shaft Femure Fracrture by Ender Versus Plate

NCT07067333 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-08-01
Last updated
2025-07-16

Condition(s) studied

Shaft Femure Fracture in Adolescents

Investigational drug(s) / intervention(s)

intramedullary nails for group Aplate for group B

intramedullary nails for group A: fixation of the shaft femure fracture in this group by intramedullary nails

plate for group B: fixation of the shaft femure fracture in the group b by plates

Study summary

The aim of this study is to compare the

* functional outcomes, fracture healing time, rate of complications, and long-term growth outcomes between intramedullary nail and plating in adolescent.
* Assess radiographic outcomes (e.g., alignment, limb length discrepancy, and growth plate disturbance).
* Evaluate complications such as infection, nonunion, malunion, refractures, and need for reoperation (e.g., hardware removal).

Eligibility

Sex
ALL
Min age
10 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Age: 10-16 years (skeletally immature, based on radiographic evidence of growth plates). * Diagnosis: Closed or open (Grade I) diaphyseal femoral fractures. * Fracture type: Simple transverse, short oblique, or spiral fractures (classified by the AO/OTA system or by the Müller classification). Exclusion Criteria: * • Fractures with significant comminution or open fractures (Grade II or III). * Pathological fractures (e.g., secondary to bone disease). * Severe systemic conditions that may affect bone healing or postoperative recovery (e.g., metabolic bone diseases). * Patients with previous ipsilateral femur fractures or those requiring re-operation for non-union or malunion.

Primary outcome measure(s)

  • Fracture Femure fixation by intramedullary nails versus plates — 6 months
    limb length discrepancy by planning X rays.

Trial sites (1)

FacilityCityRegionStatus
Sohag University Hospital Sohag Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07067333 on ClinicalTrials.gov ↗ ← All trials in Egypt